see treatment of manifestations	13	NBK1727|NBK52917|NBK3794|NBK1312|NBK1440|NBK1351|NBK1308|NBK316514|NBK65707|NBK1504|NBK1103|NBK1282|NBK1489	
hematopoietic stem cell transplantation (hsct)	5	NBK99496|NBK1127|NBK1533|NBK1162|NBK1370	
enzyme replacement therapy (ert)	5	NBK1292|NBK1269|NBK1261|NBK1274|NBK1162	
val804met+p	4	NBK1257|NBK1257|NBK1257|NBK1257	
see agents/circumstances to avoid	3	NBK1193|NBK169003|NBK143129	
see therapies under investigation	3	NBK1454|NBK1370|NBK1184	
other	3	NBK1127|NBK1369|NBK1261	
none	3	NBK333439|NBK333439|NBK333439	
8 yrs	3	NBK1257|NBK1257|NBK1257	
dietary management	3	NBK1231|NBK1319|NBK92946	
antioxidants	3	NBK1231|NBK190101|NBK84399	
prevention of secondary manifestations	2	NBK1454|NBK1429	
appropriate measures include the following:	2	NBK169615|NBK1253	
breast cancer	2	NBK1247|NBK1139	
bone marrow transplantation (bmt)	2	NBK1269|NBK1410	
prevention of acute attacks	2	NBK114807|NBK114807	
liver transplantation	2	NBK114807|NBK1231	
dietary guidelines for hereditary fructose intolerance (hfi)	2	NBK333439|NBK333439	
adapted from www	2	NBK333439|NBK333439	
edu/aldolase/hfi/treatment/sugar_table	2	NBK333439|NBK333439	
htm	2	NBK333439|NBK333439	
risk for aggressive mtc based on genotype and recommended interventions	2	NBK1257|NBK1257	
20 yrs	2	NBK1257|NBK1257	
ata = american thyroid association	2	NBK1257|NBK1257	
ser649leu and p	2	NBK1257|NBK1257	
hpt = hyperparathyroidism	2	NBK1257|NBK1257	
pathogenic variants in cis configuration on one allele	2	NBK1257|NBK1257	
criteria: normal annual basal and or stimulated serum calcitonin	2	NBK1257|NBK1257	
normal annual neck ultrasound examination	2	NBK1257|NBK1257	
family history of less aggressive mtc	2	NBK1257|NBK1257	
organ transplantation	2	NBK1231|NBK92946	
pathophysiology	2	NBK1162|NBK1162	
low-fat diet	2	NBK190101|NBK84399	
no formal guidelines for amount of dietary fat exist	2	NBK190101|NBK84399	
multiple small meals	2	NBK190101|NBK84399	
no evidence-based guidelines exist	2	NBK190101|NBK84399	
good hydration	2	NBK190101|NBK84399	
gene therapy	2	NBK1377|NBK1410	
antibiotic prophylaxis	2	NBK1178|NBK1402	
most affected individuals are clinically normal at birth	1	NBK1396	
hb bart syndrome	1	NBK1435	
no specific treatment is available for the sensorimotor neuropathy	1	NBK1372	
lifestyle and dietary modification to avoid known triggers	1	NBK1264	
bmt/sct from a “non-ideal” donor	1	NBK1483	
ert is not curative	1	NBK1483	
more than 300 affected individuals have received peg-ada	1	NBK1483	
in individuals who lack an hla-identical donor)	1	NBK1483	
chan et al 2005	1	NBK1483	
kaufman et al 2005	1	NBK1483	
husain et al 2007	1	NBK1483	
author, unpublished data]	1	NBK1483	
a third affected individual died of hepatoblastoma after 2	1	NBK1483	
5 years of ert	1	NBK1483	
these are of no clinical significance	1	NBK1483	
seek timely treatment of systemic illness or infection	1	NBK1193	
avoid excessive alcohol consumption and smoking	1	NBK1193	
regular weight-bearing exercises are encouraged to maintain bone health	1	NBK1429	
restriction of dietary protein through use of specialized formulas	1	NBK1159	
administration of oral nitrogen scavenging drugs	1	NBK1159	
9-13	1	NBK1159	
0 g/m2/day in larger patients	1	NBK1159	
diet	1	NBK51784	
arginine base supplementation	1	NBK51784	
8-15	1	NBK51784	
oral nitrogen scavenging therapy	1	NBK51784	
orthotopic liver transplantation (olt)	1	NBK51784	
management relies on personalized recommendations based on clinical assessment	1	NBK1131	
implantable cardioverter-defibrillators (icds)	1	NBK1131	
syncope was found to predict appropriate icd discharge	1	NBK1131	
class ii indications (i	1	NBK1131	
uveal melanoma	1	NBK390611	
malignant mesothelioma	1	NBK390611	
cutaneous melanoma	1	NBK390611	
complete sunblock should be used	1	NBK1151	
avoidance of triggers/stressors including trauma and surgery	1	NBK169615	
no preventive or curative treatment is available for bhds	1	NBK1522	
biotin therapy is lifelong	1	NBK1322	
a protein-restricted diet is not necessary	1	NBK1322	
branchial arch anomalies can be surgically corrected	1	NBK1380	
consider prophylactic bilateral mastectomy	1	NBK1247	
chemoprevention	1	NBK1247	
the sample size, however, was extremely small	1	NBK1247	
ovarian cancer/fallopian tube cancer	1	NBK1247	
salpingectomy	1	NBK1247	
tubal ligation	1	NBK1247	
there are no preventive measures for stroke or vascular dementia	1	NBK1500	
salt-wasting crisis	1	NBK1171	
flu prevention (i	1	NBK1328	
a later age of onset of symptoms	1	NBK1727	
strict avoidance of sunlight and protection from light are indicated	1	NBK154652	
antibacterial prophylaxis	1	NBK99496	
antifungal prophylaxis	1	NBK99496	
immunomodulatory therapy	1	NBK99496	
9 months	1	NBK99496	
13 to 0	1	NBK99496	
4 per patient year	1	NBK99496	
the data for this are anecdotal and unimpressive	1	NBK99496	
for bsa >0	1	NBK99496	
for bsa ≤0	1	NBK99496	
5/m2 the dose is 1	1	NBK99496	
5 μg/kg subcutaneously 3x/week	1	NBK99496	
allogeneic hsct is the only known cure for cgd	1	NBK99496	
, aspergillosis)	1	NBK99496	
high-carbohydrate meals and alcohol should be avoided	1	NBK1181	
arginine administration may be effective in preventing hyperammonemic crises	1	NBK1181	
aro	1	NBK1127	
a schulz and u kornak, unpublished results]	1	NBK1127	
schulz and moshous, personal communication]	1	NBK1127	
these individuals should receive prophylactic anticholinesterase therapy	1	NBK1168	
no treatment reverses or slows the natural progression of cmt	1	NBK1205	
infusions of glucose during intercurrent infections to prevent catabolism	1	NBK1253	
note: oral glucose cannot achieve this effect	1	NBK1253	
frequent meals and avoidance of extended fasting	1	NBK1253	
avoidance of prolonged exercise and other known triggers	1	NBK1253	
3 to 1	1	NBK1400	
95 g/m2/day)	1	NBK1400	
procysbi® is taken every 12 hours	1	NBK1400	
cysteamine increases gastrin synthesis and gastric acid production	1	NBK1400	
55% solution with benzalkonium chloride 0	1	NBK1400	
recommended drugs are nadolol (1-2	1	NBK1289	
granulocyte colony-stimulating factor (g-csf)	1	NBK1533	
dale, unpublished observations]	1	NBK1533	
, 5-10 µg/kg/day)	1	NBK1533	
for individuals with ts-nsan:	1	NBK1251	
prevent febrile episodes	1	NBK1251	
physical therapy may prevent early joint contractures	1	NBK1350	
as such, empiric recommendations include the following:	1	NBK220444	
supplement with levocarnitine if deficient	1	NBK220444	
avoid liver-toxic medications	1	NBK220444	
acetazolamide could stabilize channels that fail to properly inactivate	1	NBK1501	
use of soft and properly fitted clothing and footwear	1	NBK1157	
however, there is no limitation	1	NBK1244	
note: when indicated, splenectomy is curative	1	NBK190102	
2 mg/kg every 2 weeks)	1	NBK1292	
06) [banikazemi et al 2007]	1	NBK1292	
the largest comparative study is the canadian fabry disease initiative	1	NBK1292	
3 g/kg every other week	1	NBK1292	
and compliance should be closely monitored	1	NBK1292	
prophylactic anticoagulation	1	NBK1368	
pregnancy	1	NBK1368	
prophylactic anticoagulation during pregnancy:	1	NBK1368	
pharmacologic and surgical interventions have focused on palliation of symptoms	1	NBK56080	
weighted gloves can sometimes be used to assist with dysmetria	1	NBK56080	
ablative pallidotomy or thalamotomy	1	NBK56080	
colchicine	1	NBK1227	
homozygotes/compound heterozygotes	1	NBK1227	
individuals who are homozygous for the pathogenic variant p	1	NBK1227	
met694val or compound heterozygous for p	1	NBK1227	
children may need 0	1	NBK1227	
5-1 mg/day according to age and weight	1	NBK1227	
affected individuals should receive colchicine for life	1	NBK1227	
individuals who do not have the p	1	NBK1227	
glu148gln	1	NBK1227	
heterozygotes	1	NBK1227	
treatment of affected individuals who are unresponsive to colchicine	1	NBK1227	
some individuals appear to be unresponsive to colchicine treatment	1	NBK1227	
weekly intravenous colchicine (1	1	NBK1227	
this is not a long-term solution	1	NBK1227	
the possibility of interferon alpha side effects (e	1	NBK1227	
, chills and fatigue) should also be considered	1	NBK1227	
sulphasalazine	1	NBK1227	
she was homozygous for the pathogenic variant p	1	NBK1227	
dietary intervention	1	NBK1518	
, isomil® or prosobee®)	1	NBK1518	
furthermore, such tests may not be available	1	NBK51671	
, combined ert and bmt)	1	NBK1269	
it is likely that end-stage histologic changes (e	1	NBK1269	
ert is well tolerated	1	NBK1269	
adverse effects (e	1	NBK1269	
, brain, bones, and lungs)	1	NBK1269	
substrate reduction therapy (srt)	1	NBK1269	
6 to -0	1	NBK1269	
crim status	1	NBK1261	
age restrictions on lumizyme were removed in 2014	1	NBK1261	
many individuals are now treated with the higher dose	1	NBK1261	
complications of ert	1	NBK1261	
infusion-associated reactions	1	NBK1261	
prognosis	1	NBK1261	
iopd	1	NBK1261	
lopd	1	NBK1261	
the major morbidities are motor disability and respiratory insufficiency	1	NBK1261	
see treatment of manifestations and agents/circumstances to avoid	1	NBK1344	
liver phk deficiency	1	NBK55061	
hypoglycemia	1	NBK55061	
6 to 2	1	NBK55061	
some individuals may require cornstarch only before bedtime	1	NBK55061	
requirements for cornstarch tend to lessen with age	1	NBK55061	
muscle phk deficiency	1	NBK55061	
however, regular moderate aerobic exercise may be beneficial	1	NBK55061	
involves the following:	1	NBK114807	
selection of appropriate contraception for females	1	NBK114807	
a copper-eluting iud is theoretically the safest in porphyria	1	NBK114807	
however, little information exists	1	NBK114807	
suppression of menses using a gnrh agonist	1	NBK114807	
, propofol, ketamine, short-acting benzodiazepines)	1	NBK114807	
does not	1	NBK114807	
involve the following:	1	NBK114807	
use of glucose	1	NBK114807	
extreme diets (e	1	NBK114807	
no known treatment stops or slows the progression of hdl2	1	NBK1529	
5 to three years	1	NBK1404	
the following measures are recommended:	1	NBK169003	
avoidance of drugs and agents that induce the hepatic p450	1	NBK169003	
vaccination against hepatitis a and b	1	NBK169003	
table 3	1	NBK333439	
food category	1	NBK333439	
foods permitted	1	NBK333439	
foods prohibited	1	NBK333439	
dairy	1	NBK333439	
any milk, cheese, eggs	1	NBK333439	
meat	1	NBK333439	
beef, veal, lamb, pork	1	NBK333439	
ham, bacon, hot dogs, processed meats	1	NBK333439	
any other meat where sugar is used in processing	1	NBK333439	
fish	1	NBK333439	
all fish	1	NBK333439	
poultry	1	NBK333439	
chicken, turkey	1	NBK333439	
cereal	1	NBK333439	
sweetened/sugar-coated cereals	1	NBK333439	
fruit	1	NBK333439	
vegetables	1	NBK333439	
all other vegetables, including sweet potatoes	1	NBK333439	
bread	1	NBK333439	
soda crackers & saltines	1	NBK333439	
any breads or crackers prepared w/fructose/sucrose/sugar/sorbitol	1	NBK333439	
fat sources	1	NBK333439	
desserts and sweeteners	1	NBK333439	
dietetic jello, dietetic ice cream, dietetic puddings	1	NBK333439	
natural yogurt	1	NBK333439	
sugar, sucrose, sorbitol, fructose	1	NBK333439	
miscellaneous	1	NBK333439	
some sugar substitutes	1	NBK333439	
some dietetic beverages	1	NBK333439	
pasta	1	NBK333439	
rice	1	NBK333439	
cinnamon, garlic, poppy seeds	1	NBK333439	
peanut butter if prepared w/added sugars	1	NBK333439	
chewing gum w/sorbitol	1	NBK333439	
the following are recommendations:	1	NBK333439	
biopsy-proven diffuse-type gastric carcinoma	1	NBK1139	
heterozygotes for a germline cdh1 pathogenic variant	1	NBK1139	
however, the morbidity from prophylactic gastrectomy is high	1	NBK1139	
the age-specific risks of gastric cancer	1	NBK1139	
citrulline supplementation at 0	1	NBK97260	
17 g/kg/day or 3	1	NBK97260	
lysine supplementation is indicated when plasma lysine concentrations are low	1	NBK97260	
liver transplantation is not indicated for persons with hhh syndrome	1	NBK97260	
betaine therapy is usually added to the therapeutic regimen	1	NBK1524	
details about each aspect of treatment follow	1	NBK1524	
vitamin b6 (pyridoxine) therapy	1	NBK1524	
dietary treatment	1	NBK1524	
this diet should be continued indefinitely	1	NBK1524	
folate and vitamin b12 supplementation	1	NBK1524	
betaine treatment	1	NBK1524	
side effects of betaine are few	1	NBK1524	
acetazolamide treatment:	1	NBK1338	
is beneficial in approximately 50% of individuals with hokpp	1	NBK1338	
has no effect in 30% of affected individuals	1	NBK1338	
alternatives to acetazolamide	1	NBK1338	
pinacidil [ligtenberg et al 1996]	1	NBK1338	
and bumetanide [wu et al 2013]	1	NBK1338	
5 mg/kg	1	NBK1274	
more recently, in a 3	1	NBK1274	
long-term use of ert was safe	1	NBK1274	
and	1	NBK1274	
, infliximab)	1	NBK1274	
itching	1	NBK1274	
rash	1	NBK1274	
flushing	1	NBK1274	
and headache	1	NBK1274	
treatment of hyperuricemia with allopurinol can prevent development of gout	1	NBK53700	
diet/environment	1	NBK1496	
potassium-rich medications and foods (e	1	NBK1496	
, fruits, fruit juices)	1	NBK1496	
fasting	1	NBK1496	
strenuous work	1	NBK1496	
exposure to cold	1	NBK1496	
diuretics	1	NBK1496	
preventive measures include the following:	1	NBK174884	
statin-based therapy with addition of other medications as needed	1	NBK174884	
reduced intake of saturated fat	1	NBK174884	
increased intake of soluble fiber to 10-20 g/day	1	NBK174884	
increased physical activity	1	NBK174884	
not smoking	1	NBK174884	
see treatment of manifestations, clonazepam	1	NBK1260	
bmt is currently the only cure for ipex syndrome	1	NBK1118	
treatment by phlebotomy in presymptomatic stages can prevent organ damage	1	NBK1170	
treated individuals show improved and preserved cognitive function	1	NBK1238	
thiamine transporter deficiency (mutation of slc19a3)	1	NBK320989	
biotinidase deficiency (btd)	1	NBK320989	
coenzyme q10 biosynthesis defect (pdss2)	1	NBK320989	
, prolonged lethargy, depression)	1	NBK1335	
up to ten hours during the second year of life	1	NBK1424	
up to 12 hours after age two years	1	NBK1424	
to avoid excessive fasting:	1	NBK1424	
infants require frequent feedings	1	NBK1424	
a relatively low-fat diet (e	1	NBK1424	
kidney transplantation cures adtkd-umod	1	NBK1356	
the transplanted kidney does not develop the disease	1	NBK1356	
no specific treatment for melas exists	1	NBK1233	
prophylactic thyroidectomy is safe for all age groups	1	NBK1257	
table 4	1	NBK1257	
ata 1 risk level	1	NBK1257	
pathogenic variants 2, 3	1	NBK1257	
age of prophylactic surgery	1	NBK1257	
age to begin screening	1	NBK1257	
for pheo	1	NBK1257	
for hpt 4	1	NBK1257	
level d(highest risk)	1	NBK1257	
ala883phep	1	NBK1257	
met918thrp	1	NBK1257	
glu805lys 5p	1	NBK1257	
tyr806cys 5p	1	NBK1257	
ser904cys 5	1	NBK1257	
as soon as possible in 1st year of life	1	NBK1257	
level c	1	NBK1257	
cys634arg/gly/phe/ser/trp/tyr	1	NBK1257	
<5 yrs	1	NBK1257	
level b	1	NBK1257	
cys609phe/arg/gly/ser/tyrp	1	NBK1257	
cys611arg/gly/phe/ser/trp/tyrp	1	NBK1257	
cys618arg/gly/phe/ser/tyrp	1	NBK1257	
cys620arg/gly/phe/ser/trp/tyrp	1	NBK1257	
cys630arg/phe/ser/tyrp	1	NBK1257	
asp631tyrp	1	NBK1257	
633/9 bp dupp	1	NBK1257	
634/12 bp dupp	1	NBK1257	
val778ile 5	1	NBK1257	
consider <5 yrs	1	NBK1257	
may delay if criteria met 5	1	NBK1257	
level a	1	NBK1257	
arg321glyp	1	NBK1257	
531/9 bp dupp	1	NBK1257	
532 dupp	1	NBK1257	
cys515serp	1	NBK1257	
gly533cysp	1	NBK1257	
arg600glnp	1	NBK1257	
lys603glup	1	NBK1257	
tyr606cysp	1	NBK1257	
635/insert elcr	1	NBK1257	
thr636prop	1	NBK1257	
lys666glup	1	NBK1257	
glu768aspp	1	NBK1257	
asn777serp	1	NBK1257	
leu790phep	1	NBK1257	
val804leu/metp	1	NBK1257	
gly819lysp	1	NBK1257	
arg833cysp	1	NBK1257	
arg844glnp	1	NBK1257	
arg866trpp	1	NBK1257	
ser891alap	1	NBK1257	
arg912pro	1	NBK1257	
may delay beyond age 5 yrs if criteria met 6	1	NBK1257	
six months for children with men 2b	1	NBK1257	
menkes disease	1	NBK1413	
occipital horn syndrome	1	NBK1413	
medicalert	1	NBK1146	
org)	1	NBK1146	
they reflect evolving pretreatment conditioning and improved donor matching	1	NBK1130	
hsct failures continue	1	NBK1130	
nevertheless, some improvement has been seen	1	NBK1130	
nutrition	1	NBK1231	
after stabilization, nutritional management is critical	1	NBK1231	
a propiogenic amino acid-deficient formula (e	1	NBK1231	
isolated valine or isoleucine supplementation should be avoided	1	NBK1231	
hydroxocobalamin injections	1	NBK1231	
antibiotics	1	NBK1231	
rotating antibiotic regimens may be considered in some persons	1	NBK1231	
kidney transplantation	1	NBK1231	
a second patient developed progressive neurologic symptoms	1	NBK1231	
and two others developed metabolic decompensations post transplant	1	NBK1231	
adults have not undergone hsct	1	NBK1162	
all published reports indicate that ert is well tolerated	1	NBK1162	
hepatic volume normalized in 92%	1	NBK1162	
respiratory function either improved slightly or remained constant	1	NBK1162	
timed walk measurements remained largely constant	1	NBK1162	
growth resumed in approximately 70%	1	NBK1162	
the most common reactions were of an immune nature	1	NBK1162	
other studies have shown:	1	NBK1162	
5-4	1	NBK1162	
see treatment of manifestations for information regarding ert	1	NBK148668	
normal weight gain, linear growth, and head growth	1	NBK1319	
home formula supplies include bcaa-free powder	1	NBK1319	
normal age- and weight-adjusted energy intake	1	NBK1319	
appropriate leucine tolerance	1	NBK1319	
goals of laboratory monitoring:	1	NBK1319	
plasma isoleucine concentration approximately equal to plasma leucine concentration	1	NBK1319	
plasma valine concentration at least twofold plasma leucine concentration	1	NBK1319	
thiamine treatment	1	NBK1319	
9-20	1	NBK1319	
mt-rnr1-related aminoglycoside-induced ototoxicity	1	NBK1422	
thrombocytopenia cannot be prevented	1	NBK2689	
oral contraceptives are often effective in preventing or controlling menorrhagia	1	NBK2689	
exercise temporarily alleviates myotonia (the warm-up effect)	1	NBK1355	
the effect has not been systematically studied	1	NBK1355	
treatment and monitoring may then start immediately	1	NBK1177	
variable results have been reported with hsct	1	NBK1370	
enzyme replacement therapy	1	NBK1370	
skin that burns with sun exposure needs protection	1	NBK1166	
an early (pediatric) dermatologic consultation is warranted	1	NBK1166	
all primary manifestations are present at birth	1	NBK1327	
however, small meals may minimize pancreatic exocrine stimulation	1	NBK190101	
circumstances to avoid	1	NBK190101	
dehydration worsens episodes of acute pancreatitis	1	NBK190101	
no curative therapy is presently available for pbd, zss	1	NBK1448	
consistent, regular care of the conditions is necessary	1	NBK1280	
minimize intercurrent infections as environmental stressors	1	NBK6852	
5 mg for infants and 2 mg for adults	1	NBK1486	
studies have indicated that higher doses may enhance intellectual development	1	NBK1486	
such therapy is required for life	1	NBK1486	
always maintain good hydration	1	NBK395975	
avoid activities that potentially increase blood viscosity (e	1	NBK395975	
, mountain climbing, scuba diving, smoking)	1	NBK395975	
severe atp8b1 deficiency	1	NBK1297	
mild atp8b1 deficiency	1	NBK1297	
vaccination against hepatitis a and b is appropriate	1	NBK143129	
acute attack	1	NBK121283	
weekly or biweekly hemin infusions may prevent frequent noncyclical attacks	1	NBK121283	
however, published experience is lacking	1	NBK121283	
photocutaneous	1	NBK121283	
pre-prandial plasma essential amino acids	1	NBK92946	
plasma albumin	1	NBK92946	
prealbumin	1	NBK92946	
hemoglobin	1	NBK92946	
plasma ammonia	1	NBK92946	
plasma vitamin d	1	NBK92946	
essential fatty acid profile	1	NBK92946	
additional calories can be provided using protein-free formulas	1	NBK92946	
medications	1	NBK92946	
levocarnitine	1	NBK92946	
the optimal dose of levocarnitine has not been established	1	NBK92946	
levocarnitine can be given enterally and intravenously	1	NBK92946	
antimicrobial therapy	1	NBK92946	
biotin supplementation	1	NBK92946	
management during episodes of metabolic decompensation includes:	1	NBK92946	
avoidance of fasting (e	1	NBK92946	
, using intravenous dextrose)	1	NBK92946	
increasing calorie intake to prevent catabolism (e	1	NBK92946	
, intravenous fat emulsion)	1	NBK92946	
olt in patients with pa is not curative	1	NBK92946	
sedation and perioperative management	1	NBK92946	
emergency situations	1	NBK92946	
prevention of primary manifestations in hereditary pancreatitis is limited	1	NBK84399	
no curative therapy currently exists for refsum disease	1	NBK1353	
see treatment of manifestations, pharmacologic treatment	1	NBK83985	
beta blockers	1	NBK1129	
icd	1	NBK1129	
ongoing education is essential to help minimize morbidity and mortality	1	NBK1377	
maintaining hydration and avoiding extremes of climate	1	NBK1377	
monitoring for signs and symptoms requiring acute medical intervention	1	NBK1377	
early detection of chronic complications	1	NBK1377	
updates on new therapies	1	NBK1377	
chronic red blood cell transfusion therapy	1	NBK1377	
prevention of stroke recurrence	1	NBK1377	
treatment of chronic pain refractory to other therapies	1	NBK1377	
pulmonary hypertension	1	NBK1377	
chronic renal failure	1	NBK1377	
recurrent episodes of acs	1	NBK1377	
severe end-organ damage	1	NBK1377	
metabolism into nitric oxide, a potent vasodilator	1	NBK1377	
overall improvement in blood flow	1	NBK1377	
reduction of vascular inflammation	1	NBK1377	
hydroxyurea can have potentially significant toxicity, including myelosuppression	1	NBK1377	
gov/ct2/show/nct01179217)	1	NBK1377	
orthotopic liver transplantation (oltx)	1	NBK1194	
age younger than 60 years	1	NBK1194	
disease duration less than five years	1	NBK1194	
no significant cardiac or renal dysfunction	1	NBK1194	
fapwtr	1	NBK1194	
org/ram_fap	1	NBK1194	
severe polyneuropathy (norris score <55/81)	1	NBK1194	
permanent urinary incontinence	1	NBK1194	
marked postural hypotension	1	NBK1194	
a fixed pulse rate	1	NBK1194	
[behrend et al 2012]	1	NBK6816	
however, the efficacy remains controversial	1	NBK6816	
severe exercise (e	1	NBK6816	
infection	1	NBK1178	
intravenous immune globulin	1	NBK1178	
routine childhood immunizations	1	NBK1178	
live vaccines should be avoided	1	NBK1178	
bleeding	1	NBK1178	
splenectomy	1	NBK1178	
platelet transfusions	1	NBK1178	
platelet transfusions should be administered judiciously (e	1	NBK1178	
, for significant bleeding and surgical procedures)	1	NBK1178	
hla-matched bone marrow transplantation from a relative is preferred	1	NBK1410	
cord blood from normal infants is now being banked	1	NBK1410	
bmt after age 3	1	NBK1410	
administration of immunoglobulin	1	NBK1410	
see also therapies under investigation	1	NBK1410	
bacterial infections	1	NBK1453	
both routes provide good therapeutic concentrations of serum igg	1	NBK1453	
a variety of brands of gammaglobulin are available	1	NBK1453	
such reactions may disappear over time	1	NBK1453	
the following methods are used to prevent infection:	1	NBK1402	
intravenous immune globulin (ivig)	1	NBK1402	
outcomes are the best with hla-matched, related donors	1	NBK20221	
matched unrelated donor	1	NBK20221	
umbilical cord blood donor	1	NBK20221	
all individuals were alive at a median of 13	1	NBK20221	
5 years of follow up	1	NBK20221	
two individuals receiving myeloablative conditioning have developed premature ovarian failure	1	NBK20221	
